PILA trial: Levofloxacin vs piperacillin/sulbactam and sultamicillin in patients with acute cholecystitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN88750971

Enrollment

142

Registered

2008-06-12

Start date

2008-04-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute cholecystitis Digestive System Cholecystitis

Interventions

Control group: Piperacillin 4 g or sulbactam 1 g intravenously (i.v.) 3 x daily for 2 days, then sultamicillin 0.75 g orally (p.o.) 2 x daily for 2 - 8 days. Experimental group: Levofloxacin 0.5 g i

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Clinical signs of acute cholecystitis 2. Acute cholecystitis identified by transabdmonial ultrasound 3. Elevated infection parameters 4. Age 18-90 years

Exclusion criteria

Exclusion criteria: 1. Potential other cause of infection 2. Pregnancy 3. Psychiatric disease 4. Penicillin incompatibility 5. Fluorochinolon incompatibility 6. Renal failure 7. AIDS 8. Liver cirrhosis 9. Seizure disorder

Design outcomes

Primary

Measure	Time frame
Number of days in hospital (in-patient)	—

Secondary

Measure	Time frame
The following will be monitored during the treatment: 1. Change of antibiotic therapy 2. Duration of antibiotic therapy 3. Fever 4. Laboratory parameters 5. Complications of antibiotic therapy	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026